This is the authors' abstract. We don't add key points for this paper.
A 58-year-old patient with a history of diabetic nephropathy presented with a flare-up of his long-standing pemphigus vulgaris, for which he received a new therapy. His blood workup showed mildly increased kappa light chains 27.3 (3.3 to 19.4) mg/L with a normal kappa/lambda ratio. Serum electrophoresis and immunofixation showed normal protein fractions with a nonquantifiable IgG kappa monoclonal band in the distal/cathodal region (Fig. 1). Urine analysis revealed albuminuria at 410 (0 to 29) mg/g creatinine (46.3 [0 to 3.3] mg/mmol), but no monoclonal proteins on electrophoresis/immunofixation. ... ... The answers are on the next page. This electrophoretic pattern is suggestive of therapeutic monoclonal antibody (tmAb) interference. Far-cathodal band migration is characteristic for rituximab (1). The patient chart showed that the sample was collected post-rituximab. We reported: “Faint IgG kappa monoclonal band, possible rituximab interference. Recommend retesting shortly before next rituximab administration.” Rituximab (28 mg/dL), but no intrinsic monoclonal protein, was reported by mass spectrometry. Mass spectrometry recognizes any tmAbs (2, 3), while Hydrashift immunofixation detects daratumumab and isatuximab specifically (4, 5). Immunofixation on a subsequent specimen was negative.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ianosi-Irimie et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: